50-07-7 MSDS - Mitomycin C
Online Database of Chemicals Bookmark and Share English Deutsch 한국어

MSDS-CAS.COM / Home >> Chemical Database >> 50-07-7
 




Mitomycin C

Identification
Name Mitomycin C
CAS Registry Number 50-07-7
Synonyms )methyl)-1,1a,2,8,8a,8b-hexahydro-8-a-methoxy-5-methyl-,(1as-(1aalpha,8beta,;7-amino-9-alpha-methoxymitosane;8aalpha,8balpha))-(9ci);8balpha)]-8aalph;ametycine;azirino(2’,3’:3,4)pyrrolo(1,2-a)indole-4,7-dione,6-amino-1,1a,2,8,8a,8b-hexahy;azirino(2’,3’:3,4)pyrrolo(1,2-a)indole-4,7-dione,6-amino-8-(((aminocarbonyl)oxy;azirino[2’,3’:3,4]pyrrolo[1,2-a]indole-4,7-dione,6-amino-8-[[(aminocarbonyl)ox
Molecular Structure Mitomycin C   50-07-7
Molecular Formula C15H18N4O5
Molecular Weight 334.33
mp: 360 ℃
Hazard Codes: Details
Risk Statements: 25-40-22-45-26/27/28
Safety Statements: 36/37-45-28A-28-53-22
RIDADR: UN 3462 6.1/PG 2
Supplier
Lightchem Inc
Supply Precious metal catalyst
OLED Materials etc.
www.lightchem.com
 
Wiki & MSDS
50-07-7.pdf
Mitomycin C
Mitomycin.svg
Mitomycin ball-and-stick.png
Clinical data
Pregnancy
category
  • AU: D
  • US: D (Evidence of risk)
Legal status
Legal status
  • UK: POM (Prescription only)
  • US: ℞-only
Pharmacokinetic data
Metabolism Hepatic
Biological half-life 8–48 min
Identifiers
CAS Number
  • 50-07-7
PubChem CID
  • 5746
PubChem SID
  • 44286993
IUPHAR/BPS
  • 7089
DrugBank
  • DB00305
ChemSpider
  • 5544
UNII
  • 50SG953SK6
KEGG
  • C06681
ChEBI
  • CHEBI:27504
ChEMBL
  • CHEMBL105
ECHA InfoCard 100.000.008
Chemical and physical data
Formula C15H18N4O5
Molar mass 334.33 g·mol−1
3D model (Jmol)
  • Interactive image
Melting point 360 °C (680 °F)
Solubility in water 8.43 g L−1 mg/mL (20 °C)

Mitomycin C is a mitomycin that is used as a chemotherapeutic agent by virtue of its antitumour activity. It is given intravenously to treat upper gastro-intestinal cancers (e.g. esophageal carcinoma), anal cancers, and breast cancers, as well as by bladder instillation for superficial bladder tumours. It causes delayed bone marrow toxicity and therefore it is usually administered at 6-weekly intervals. Prolonged use may result in permanent bone-marrow damage. It may also cause lung fibrosis and renal damage.

Mitomycin C has also been used topically rather than intravenously in several areas. The first is cancers, particularly bladder cancers and intraperitoneal tumours. It is now well known that a single instillation of this agent within 6 hours of bladder tumor resection can prevent recurrence. The second is in eye surgery where mitomycin C 0.02% is applied topically to prevent scarring during glaucoma filtering surgery and to prevent haze after PRK or LASIK; mitomycin C has also been shown to reduce fibrosis in strabismus surgery.[1] The third is in esophageal and tracheal stenosis where application of mitomycin C onto the mucosa immediately following dilatation will decrease re-stenosis by decreasing the production of fibroblasts and scar tissue.

Mitomycin C is a potent DNA crosslinker. A single crosslink per genome has shown to be effective in killing bacteria. This is accomplished by reductive activation of mitomycin to form a mitosene, which reacts successively via N-alkylation of two DNA bases. Both alkylations are sequence specific for a guanine nucleoside in the sequence 5'-CpG-3'.[2] Potential bis-alkylating heterocylic quinones were synthetised in order to explore their antitumoral activities by bioreductive alkylation.[3] Mitomycin is also used as a chemotherapeutic agent in glaucoma surgery.


 







Oxyphenonium bromide 50-10-2
METHARBITAL CIII (200 MG) 50-11-3
(S)-MEPHENYTOIN 50-12-4
MEPERIDINE HYDROCHLORIDE 50-13-5
Vitamin D2 50-14-6
Cyclophosphamide 50-18-0
oxyfenamate 50-19-1
SUCROSE-UL-14C SOLUTION 50-20-4
Lactic acid 50-21-5
CORTICOSTERONE 50-22-6

Content Disclaimer | About | Contact us| Ads

©  MSDS-CAS. All rights reserved.